AI-generated · cited to primary sources · not investment advice · How we research
Dr Agarwal's Hea
Our verdict on Dr Agarwal's Hea isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
Overall EBITDA margins for H2 FY26 are expected to remain at similar levels to H1 FY26 due to expansion pace.
“But in terms of the overall margins with the pace of expansion and with more Greenfields getting launched, the overall margins on a percentage basis should be on similar levels as to whatever we have reported on for H1, Tushar”
Management expects new facilities in non-core markets to reach breakeven within 15 to 18 months.
“However, we expect the facilities to broadly breakeven around the 15 to 18”
Expectation of 4.5% to 5% growth in realization due to premiumization in cataract surgeries.
“We are seeing a good amount of increase in premiumization, and that has been around 4.5% to 5% for this quarter. We hope to continue with that kind of growth over the next few quarters”
Management is focused on attracting and retaining a qualified team of medical professionals through research opportunities and a robust career development program.
“Talent ✓ Continuous Learning and Research Opportunities for Doctors ✓ Strong Network Effects from Robust Career Development Program”
Management intends to selectively relocate mature facilities to cater to high demand areas.
“Selective relocation of mature facilities to cater to high demand”
See the full cited Management analysis of Dr Agarwal's Hea
How durable is the business?
Surgical revenues remain the dominant pillar, with volumes growing 28% year-on-year for the full year. High-end cataract surgeries increased their contribution to the mix.
“in FY '25, the surgical revenues form the main pillar of our service offering, contributing to”
The company is aggressively expanding its footprint, adding 59 facilities in FY25 and targeting another 55-60 in FY26, with a focus on the southern states and Maharashtra.
“Looking ahead, in FY '26, we are targeting a launch of 55 to 60 facilities”
Adoption of high-end technology is accelerating, specifically in laser cataract (Femto) and refractive surgery (SMILE), which is driving premiumization.
“increase in contribution coming in from high-end cataract surgeries, which has moved up from 19”
The revenue contribution from India has increased as the company focuses on domestic expansion, particularly in Tier 2 and Tier 3 cities.
“There has been greater focus on India, with its contribution to the overall group revenue increasing from 87.2% in FY '24 to 89.9% in FY '25. Revenue from operations in India for FY '25 totaled INR1538 crores, marking a growth of 32.3% year-on-year”
Revenue from opticals and pharmaceuticals grew 27.5% but its share of the total revenue mix remained stable at approximately 20.8%.
“Opticals, Contact Lens, and Accessories & Pharmaceutical Products 20.8%”
See the full cited Business Model analysis of Dr Agarwal's Hea
Where does growth come from?
The company is building a 'Doctor Flywheel' by rapidly hiring and retaining specialists, which acts as a competitive moat in the healthcare industry.
“908 Doctors and 2,052 Paramedical Staff”
The adoption of high-end laser-assisted (Femto) cataract surgeries is accelerating, with contribution to total cataract volume rising from 19.2% in FY24 to 22.5% in FY25.
“increase in contribution coming in from high-end cataract surgeries, which has moved up from 19.2% in FY '24 to 22.5% in FY '25”
Refractive surgery (vision correction) is showing explosive growth, significantly outpacing the core cataract segment.
“We have also seen an uptick in the refractive surgery segment, where we witnessed a 44% overall growth in the number of surgeries, and we have done 15,989 refractive surgeries in the year FY '25”
The geographic expansion is accelerating, particularly in North and West India, moving away from a South-only concentration.
“30.6% CAGR Growth in Total Facilities over FY2022 – FY2025”
Full-year PAT grew 16% to INR 110 crores, but management is projecting a significant acceleration to 35%+ growth for FY26.
“Our profit after tax stood at INR110 crores, reflecting a 16% year-on-year growth”
See the full cited Future Growth analysis of Dr Agarwal's Hea
What could break the thesis?
Geographic concentration remains high but is gradually diversifying. Revenue from the South region decreased from 64% to 63.1% of the payor mix, and the company is aggressively expanding into the North (Delhi NCR, Punjab) and West (Gujarat).
“Approximately 65% of our Indian network is present in cities beyond the top metropolitan areas”
The risk is intensifying as the company plans to accelerate expansion to 55-60 new facilities in FY26 (up from 59 in FY25), with a significant capex of INR 310 crores.
“Looking ahead, in FY '26, we are targeting a launch of 55 to 60 facilities”
The company continues a rapid expansion cycle, growing total facilities at a 29.7% CAGR from FY22 to Q1 FY26. While this drives revenue, it maintains pressure on margins as new centers ramp up.
“29.7% CAGR Growth in Total Facilities over FY22 – Q1FY26”
Management expects EBITDA margins to remain stable despite ongoing greenfield investments, but the sheer volume of new openings (55-60) keeps this risk elevated.
“We expect our EBITDA margin to remain stable as ongoing greenfield investments continue to impact profitability”
Execution risk remains high as the company added 59 new facilities in FY25. The EBITDA margin saw a slight decline from 29.5% in FY24 to 28.6% in FY25 due to the ramp-up of these new centers.
“We added 59 new facilities this year”
See the full cited Risk analysis of Dr Agarwal's Hea
Read the full thesis on Dr Agarwal's Hea
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.